Nels joins TWiV to discuss hypotheses for the origins of Omicron, including that it came from mice or arose during chronic infection of an immunocompromised patient. Hosts: Vincent Racaniello, Rich Condit, Kathy Spindler, and Brianne Barker Guest: Nels Elde Click arrow to playDownload TWiV 861 (69 MB .mp3, 114 min)Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Show notes …
In COVID-19 clinical update #99, Daniel Griffin discusses Omicron disease severity, neurologic manifestations in children, testing outcomes during multiple infections, boosters improve VE and VD, booster efficacy for ED and UC encounters, vaccines induce cross-protective T cell memory, and indications for monoclonal antibody therapy.
TWiV reviews findings that increased fitness of the Omicron variant is due to immune evasion, not an increase in intrinsic transmissibility, and determination of infectious viral load in patients infected with wild type, Delta and Omicron viruses reveals lack of correlation with RNA loads determined by RT-PCR, similar levels of shedding among Delta and Omicron, …
In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for …
TWiV 853: COVID-19 clinical update #97 with Dr. Daniel Griffin Read More »
In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID. Click arrow to playDownload TWiV 850 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show notes at microbe.tv/twiv
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients. Hosts: Daniel Griffin and Vincent Racaniello Click arrow to playDownload TWiV 845 (58 MB .mp3, 48 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Show …
TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin Read More »
